The in vitro activities of voriconazole, posaconazole, ravuconazole and micafungin were compared with those of fluconazole, itraconazole, ketoconazole, flucytosine and amphotericin B against 164 candidaemia isolates recovered from cancer patients in two Canadian centres. The MIC 50 results for ravuconazole, voriconazole, posaconazole and micafungin were 0.01, 0.03, 0.12 and 0.25 mg/L, respectively. The new antifungal agents showed substantial activity against isolates demonstrating in vitro resistance to fluconazole and itraconazole. These results suggest that the newer antifungal agents possess promising activity against invasive Candida isolates, particularly against those with reduced susceptibility to fluconazole and itraconazole.
Introduction
Candida bloodstream infections are important causes of morbidity and mortality in immunosuppressed cancer patients. 1 Although fluconazole and itraconazole have been shown to be effective against invasive candidiasis in compromised hosts, emerging resistance gives rise to concerns about their future clinical usefulness. 2 Several new investigational triazole agents and new echinocandin-like lipopeptides, which have a unique mode of action by disruption of cell wall glucan formation, may represent promising agents against yeast isolates with primary or secondary resistance to fluconazole and/or itraconazole. 3, 4 We compare the in vitro activity of three new triazoles, voriconazole, posaconazole and ravuconazole, and one echinocandin-like lipopeptide, micafungin, with that of established agents against Candida from bloodstream infections in cancer patients treated in two different Canadian medical centres.
Materials and methods
A total of 164 Candida spp. isolates, recovered between 1996 and 2000 from blood cultures of cancer patients treated at Hôpital Maisonneuve-Rosemont (HMR) and the Health Sciences Center (HSC), were selected for testing. Standard antifungal powders of amphotericin B (Nucro Technics, Scarborough, Ontario, Canada), ravuconazole (BristolMyers Squibb Pharmaceutical Research Institute, Wallingford, CT, USA), flucytosine (ICN Canada, Toronto, Ontario, Canada), ketoconazole, itraconazole (Janssen Research Foundation, Beerse, Belgium), fluconazole, voriconazole (Pfizer Pharmaceuticals, New York, NY, USA), posaconazole (Schering-Plough Research Institute, Kenilworth, NJ, USA) and micafungin (Fujisawa Healthcare, Inc., Osaka, Japan) were supplied by their respective manufacturers. Stock solutions were prepared in dimethyl sulphoxide for ravuconazole, voriconazole, posaconazole, itraconazole, amphotericin B and ketoconazole, or in water in the case of the other antifungal agents. Serial two-fold dilutions were made in RPMI 1640 medium (Sigma, St Louis, MO, USA) buffered to pH 7.0 with 0.165 M morpholinepropanesulphonic acid (MOPS) buffer (Sigma) for all antifungals, with the exception of amphotericin B, for which antibiotic medium 3 plus 2% glucose was used as the test medium to enable a more reliable detection of resistant isolates. 5 The final concentration of the solvent did not exceed 1% in any of the wells. Antifungal susceptibility testing was performed by a broth microdilution method according to the guidelines recommended by the NCCLS. 6 The final concentrations of the antifungal agents were: 0.006-64 mg/L of flucytosine; 0.008-8 mg/L of amphotericin B, itraconazole, voriconazole, ravuconazole, posaconazole and micafungin; 0.016-16 mg/L dkf074.fm of ketoconazole; and 0.25-256 mg/L of fluconazole. Drugand yeast-free controls were included. The trays were incubated in air at 35°C and MIC endpoints were read after 48 h of incubation. Following incubation, the trays were examined visually and the growth in each well was compared with the growth of the control (drug-free) well. The MIC of amphotericin B was defined as the lowest concentration resulting in a complete inhibition of growth, whereas the MICs of all the other compounds were defined as the lowest concentration that resulted in a prominent decrease in turbidity compared with that of growth-control wells, using the turbidity numerical score proposed by the NCCLS. 6 The MIC 50 and MIC 90 results are the concentrations of each antifungal agent necessary to inhibit 50% and 90% of the isolates, respectively. Candida parapsilosis ATCC 22019, Candida kruseï ATCC 6258 and a fluconazole-resistant Candida albicans were included as quality control isolates.
Results and discussion
The 164 isolates were evenly distributed between the two participating centres, with a similar proportion of C. albicans versus non-albicans Candida species (54% versus 46% for HMR and 50% versus 50% for HSC). The in vitro susceptibilities of the isolates are summarized in Table 1 . A broad range of MICs was observed with both the current and the new investigational antifungal agents. Overall, ravuconazole was the most potent agent (MIC 90 0.25 mg/L), followed by voriconazole, posaconazole, ketoconazole, itraconazole, amphotericin B (MIC 90 In general, compared with the current antifungal agents, the new investigational triazoles and echinocandins have been shown to have increased in vitro potencies against Candida isolates. 7-9 In our study, ravuconazole, voriconazole and posaconazole were, respectively, 15-, 10-and four-fold more active than fluconazole against fluconazole-and itraconazolesusceptible isolates, and up to three-fold more active than itraconazole against those same susceptible isolates. The newer triazoles and micafungin showed greater activity against isolates with reduced susceptibility to fluconazole and/or itraconazole, by 12-to 85-fold compared with fluconazole and up to six-fold compared with itraconazole.
There are important pharmacokinetic differences between these various antifungal agents and this, combined with the fact that for the newer agents no susceptibility breakpoints have been established so far, means that the clinical impact of these different in vitro potencies will have to be determined through clinical studies. Substantial variation in the activities of the new antifungals, particularly against non-albicans Candida, are occasionally observed between studies. In our study we observed a limited activity of posaconazole against C. tropicalis, which contrasts with the observations made by Pfaller et al. 9 The limited number of C. tropicalis isolates in our study, and the fact that 12 of these 21 isolates had reduced susceptibility to fluconazole and/or itraconazole, may explain this apparent disagreement, since cross-resistance with new triazoles has been documented by Hong-Nguyen & Yu. 3 Of the three C. tropicalis isolates with posaconazole MICs > 8 mg/L, two showed fluconazole MICs of 128 and 256 mg/L, respectively. Similarly, micafungin was less active against C. parapsilosis. Lesser activity of echinocandins against C. parapsilosis has previously been observed by others. 4, [7] [8] [9] The clinical relevance of such an observation is presently unknown, since standardization of the susceptibility testing methods to assess the in vitro activity of the echinocandin lipopeptides has not been clearly defined, and breakpoints have not yet been determined. Reproducible interlaboratory results, obtained using the currently recommended NCCLS microdilution method against Candida isolates, have been reported with one of the new echinocandin agents. 10 However, NCCLS methodology may not be suitable for this class of antifungals, and correlation between the in vitro and in vivo responses has not yet been established.
In conclusion, ravuconazole, posaconazole, voriconazole and the echinocandin micafungin exhibited good in vitro activity against our bloodstream isolates of Candida from cancer patients. They also demonstrate remarkable in vitro activity against isolates with reduced susceptibility to fluconazole and/or itraconazole. These new antifungal agents may hold promise in the management of invasive candidiasis caused by yeasts with primary and/or secondary resistance to established triazole agents. dkf074.fm 
